NUCB2 inhibition antagonizes osteosarcoma progression and promotes anti-tumor immunity through inactivating NUCKS1/CXCL8 axis
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.216893 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Renchen Ji und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Second Affiliated Hospital, Dalian Medical University, Dalian, Liaoning 116044, China. Hauptthemen laut MEDLINE: Bone Neoplasms, Calcium-Binding Proteins, Disease Progression, Interleukin-8. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Liaoning Provincial Natural Science Foundation.
Abstract (Originalsprache)
The oncogenic properties of Nucleobindin2 (NUCB2) have been observed in various cancer types. Nevertheless, the precise understanding of the biological functions and regulatory mechanisms of NUCB2 in osteosarcoma remains limited. This investigation reported that NUCB2 was significantly increased upon glucose deprivation-induced metabolic stress. Elevated NUCB2 suppressed glucose deprivation-induced cell death and reactive oxygen species (ROS) increase. Depletion of NUCB2 resulted in a reduction in osteosarcoma cell proliferation as well as metastatic potential in vitro and in vivo. Mechanically, NUCB2 ablation suppressed C-X-C Motif Chemokine Ligand 8 (CXCL8) expression which then reduced programmed cell death 1 ligand 1 (PD-L1) expression and stimulated anti-tumor immunity mediated through cytotoxic T cells. Importantly, a combination of NUCB2 depletion with anti-PD-L1 treatment improved anti-tumor T-cell immunity in vivo. Moreover, we further demonstrated that NUCB2 interacted with NUCKS1 to inhibit its degradation, which is responsible for the transcriptional regulation of CXCL8 expression. Altogether, the outcome emphasizes the function of NUCB2 in osteosarcoma and indicates that NUCB2 elevates osteosarcoma progression and immunosuppressive microenvironment through the NUCKS1/CXCL8 pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second Affiliated Hospital, Dalian Medical University, Dalian, Liaoning 116044, China.
- Dalian NO.3 People's Hospital, Department of Orthopedics, Dalian, Liaoning 116044, China.
- Institute of Cancer Stem Cell, Dalian Medical University, Dalian, Liaoning 116044, China.
- The Second Affiliated Hospital, Dalian Medical University, Dalian, Liaoning 116044, China. Electronic address: drzwz@163.com.
- College of Stomatology Dalian Medical University, Dalian 116044, China. Electronic address: xiaojieli0504@dmu.edu.cn.
- Institute of Cancer Stem Cell, Dalian Medical University, Dalian, Liaoning 116044, China. Electronic address: hanchuanchun@163.com.
Förderung
- National Natural Science Foundation of China
- Liaoning Provincial Natural Science Foundation
Zitieren
APA
Ji, R., Wang, Y., Pan, D., Han, J., Wang, Y., Zheng, S., Zhao, W., Li, X., Han, C., & Zhang, L. (2024). NUCB2 inhibition antagonizes osteosarcoma progression and promotes anti-tumor immunity through inactivating NUCKS1/CXCL8 axis. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.216893
Vancouver
Ji R, Wang Y, Pan D, Han J, Wang Y, Zheng S, et al. NUCB2 inhibition antagonizes osteosarcoma progression and promotes anti-tumor immunity through inactivating NUCKS1/CXCL8 axis. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.216893
BibTeX
@article{Ji2024,
author = {Ji, Renchen and Wang, Yuan and Pan, Deyue and Han, Jian and Wang, Yiping and Zheng, Shuo and Zhao, Wenzhi and Li, Xiaojie and Han, Chuanchun and Zhang, Lu},
title = {NUCB2 inhibition antagonizes osteosarcoma progression and promotes anti-tumor immunity through inactivating NUCKS1/CXCL8 axis},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.216893}
}
EUVIMED